| Autor: |
Sureja V; Department of Medical Affairs, Sundyota Numandis Group of Companies, Ahmedabad, India., Kheni D; Department of Medical Affairs, Sundyota Numandis Group of Companies, Ahmedabad, India., Prajapati D; Department of Medical Affairs, Sundyota Numandis Group of Companies, Ahmedabad, India., Rajawat M; Department of Medical Affairs, Sundyota Numandis Group of Companies, Ahmedabad, India., Magar A; Department of Medical Affairs, Sundyota Numandis Group of Companies, Ahmedabad, India., Krishnaraj A; Department of Medical Affairs, Sundyota Numandis Group of Companies, Ahmedabad, India., Sirsikar A; Department of Orthopedics, N.S.C.B Medical College, Jabalpur, India., Prasath AA; Department of Orthopedics, APJ Multi-Speciality Hospital, Walajabad, India., Mishra A; Department of Orthopedics, Suchak Hospital, Mumbai, India., Rajput AS; Department of Orthopedics, Rajput Fracture, Joint & Trauma Clinic, Gwalior, India., Vijayakrishnan B; Department of Orthopedics, Lifespan Bone & Joint Clinic, Chennai, India., Puram C; Department of Orthopedics, Sancheti Institiute for Orthopaedic & Rehabilitation, Pune, India., Kumar DM; Department of Orthopedics, Shri Kanaka Mahalaxmi Nursing Home, Vizag, India., Agarwal D; Department of Orthopedics, Diwakar Ortho & General Hospital, Jaipur, India., Shiragambhi G; Department of Orthopedics, Primus Hospital, Bengaluru, India., Patil J; Department of Orthopedics, Adarsh Nursing Home, Mumbai, India., Ravichandran K; Deparment of Orthopedics, Jayam Hospital, Madurai, India., Jain KN; Department of Orthopedics, Dr. Jain's Clinic, Delhi, India., Raju MT; Department of Orthopedics, Radhika Clinic, Bengaluru, India., Arora R; Department of Orthopedics, Newlife Clinic, Delhi, India., Nawazish S; Department of Orthopedics, Nuha Hospital, Guntur, India., Chhabra S; Department of Orthopedics, Pusp Clinic, Indore, India., Shyam L; Department of Orthopedics, Raksha Hospital, Madurai, India., Is S; Department of Orthopedics, Bhargav Orthopedic Center & Banashankari Orthopedic Speciality Service, Bengaluru, India., Aggarwal V; Department of Orthopedics, Sanjeevani Hospital, Delhi, India. |
| Abstrakt: |
Background: Chronic low back pain (LBP) is the most common musculoskeletal condition affecting a person's quality of life. Over the past decades, a lot of work was done in an attempt to reduce the negative impact of LBP, and help patients recover and maintain a better quality of life. Nevertheless, there is still a lot to be done to fully understand the problem of underlying chronic LBP and a wide gap that exist between basic science and applied rehabilitation research on LBP. Objectives: This was an open label, multicentric, observational, post-marketing surveillance study in a real-world setup designed to evaluate the efficacy and safety of MyrliMax® capsules containing standardised Commiphora myrrha gum resin extract in Indian subjects with chronic LBP varying in intensity. Materials and methods: This study included 204 subjects diagnosed with chronic LBP at the outpatient department of 20 centres under the supervision of a medical doctor. All subjects took MyrliMax® capsules twice daily for 20 days. Visual Analogue Scale (VAS) pain score, rescue medicine requirement, therapy satisfaction scores and safety parameters were assessed as per the schedule. Outcomes: Treatment with MyrliMax® capsules significantly (p<0.01) and progressively reduced the VAS score throughout treatment. A significant pain reduction was observed from the second visit. The mean VAS score was 6.58, 4.66, 2.99 and 1.88 on Day 0, Day 7, Day 14 and Day 20, respectively. A similar trend was also observed in subgroups based on gender and severity score. The need of rescue analgesics/NSAIDs was significantly reduced from the second week, indicating a potential of MyrliMax® capsules to increase the pain threshold. All physicians and patients were satisfied with the efficacy of MyrliMax® capsules assessed by physician's satisfaction score and patient's satisfaction score. There were no significant serious adverse events due to treatment during the study, which indicated that the treatment with MyrliMax® was well tolerated by subjects. Conclusion: MyrliMax® capsule is a potentially effective and safe therapy for pain reduction in patients suffering from chronic LBP. MyrliMax® capsules can be used to reduce pain in NSAIDs intolerant subjects suffering from chronic LBP. |
